Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis.

Graubert TA, Payton MA, Shao J, Walgren RA, Monahan RS, Frater JL, Walshauser MA, Martin MG, Kasai Y, Walter MJ.

PLoS One. 2009;4(2):e4583. doi: 10.1371/journal.pone.0004583. Epub 2009 Feb 25.

2.

Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.

Mallo M, Arenillas L, Espinet B, Salido M, Hernández JM, Lumbreras E, del Rey M, Arranz E, Ramiro S, Font P, González O, Renedo M, Cervera J, Such E, Sanz GF, Luño E, Sanzo C, González M, Calasanz MJ, Mayans J, García-Ballesteros C, Amigo V, Collado R, Oliver I, Carbonell F, Bureo E, Insunza A, Yañez L, Muruzabal MJ, Gómez-Beltrán E, Andreu R, León P, Gómez V, Sanz A, Casasola N, Moreno E, Alegre A, Martín ML, Pedro C, Serrano S, Florensa L, Solé F.

Haematologica. 2008 Jul;93(7):1001-8. doi: 10.3324/haematol.13012.

3.

The molecular pathogenesis of the myelodysplastic syndromes.

Pellagatti A, Boultwood J.

Eur J Haematol. 2015 Jul;95(1):3-15. doi: 10.1111/ejh.12515. Epub 2015 Feb 20. Review.

PMID:
25645650
4.

A cryptic deletion in 5q31.2 provides further evidence for a minimally deleted region in myelodysplastic syndromes.

MacKinnon RN, Kannourakis G, Wall M, Campbell LJ.

Cancer Genet. 2011 Apr;204(4):187-94. doi: 10.1016/j.cancergen.2011.02.001.

PMID:
21536236
5.
6.

Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears.

Bigoni R, Cuneo A, Milani R, Cavazzini F, Bardi A, Roberti MG, Agostini P, della Porta M, Specchia G, Rigolin GM, Castoldi G.

Haematologica. 2001 Apr;86(4):375-81.

7.

Deletion of 5q31 is observed in megakaryocytic cells in patients with myelodysplastic syndromes and a del(5q), including the 5q- syndrome.

Godon C, Talmant P, Garand R, Accart F, Bataille R, Avet-Loiseau H.

Genes Chromosomes Cancer. 2000 Dec;29(4):350-2.

PMID:
11066080
8.

Deletion 5q MDS: molecular and therapeutic implications.

Komrokji RS, Padron E, Ebert BL, List AF.

Best Pract Res Clin Haematol. 2013 Dec;26(4):365-75. doi: 10.1016/j.beha.2013.10.013. Epub 2013 Oct 16. Review.

PMID:
24507813
9.

Molecular dissection of the 5q deletion in myelodysplastic syndrome.

Ebert BL.

Semin Oncol. 2011 Oct;38(5):621-6. doi: 10.1053/j.seminoncol.2011.04.010. Review.

10.

Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.

Liu TX, Becker MW, Jelinek J, Wu WS, Deng M, Mikhalkevich N, Hsu K, Bloomfield CD, Stone RM, DeAngelo DJ, Galinsky IA, Issa JP, Clarke MF, Look AT.

Nat Med. 2007 Jan;13(1):78-83. Epub 2006 Dec 10.

PMID:
17159988
11.

The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.

Stengel A, Kern W, Haferlach T, Meggendorfer M, Haferlach C.

Genes Chromosomes Cancer. 2016 Oct;55(10):777-85. doi: 10.1002/gcc.22377. Epub 2016 Jul 4.

PMID:
27218649
12.

Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.

Fernandez-Mercado M, Burns A, Pellagatti A, Giagounidis A, Germing U, Agirre X, Prosper F, Aul C, Killick S, Wainscoat JS, Schuh A, Boultwood J.

Haematologica. 2013 Dec;98(12):1856-64. doi: 10.3324/haematol.2013.086686. Epub 2013 Jul 5.

13.

Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice.

Chen TH, Kambal A, Krysiak K, Walshauser MA, Raju G, Tibbitts JF, Walter MJ.

Blood. 2011 Feb 3;117(5):1530-9. doi: 10.1182/blood-2010-06-293167. Epub 2010 Dec 1.

14.

Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases.

Le Beau MM, Espinosa R 3rd, Neuman WL, Stock W, Roulston D, Larson RA, Keinanen M, Westbrook CA.

Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5484-8.

15.

Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.

Evers C, Beier M, Poelitz A, Hildebrandt B, Servan K, Drechsler M, Germing U, Royer HD, Royer-Pokora B.

Genes Chromosomes Cancer. 2007 Dec;46(12):1119-28.

PMID:
17823930
16.

5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.

Eisenmann KM, Dykema KJ, Matheson SF, Kent NF, DeWard AD, West RA, Tibes R, Furge KA, Alberts AS.

Oncogene. 2009 Oct 1;28(39):3429-41. doi: 10.1038/onc.2009.207. Epub 2009 Jul 13. Review.

PMID:
19597464
17.

Deletions of chromosome 5 in malignant myeloid disorders.

Le Beau MM.

Cancer Surv. 1992;15:143-59. Review.

PMID:
1451109
18.

Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.

Keerthivasan G, Mei Y, Zhao B, Zhang L, Harris CE, Gao J, Basiorka AA, Schipma MJ, McElherne J, Yang J, Verma AK, Pellagatti A, Boultwood J, List AF, Williams DA, Ji P.

Blood. 2014 Jul 31;124(5):780-90. doi: 10.1182/blood-2014-01-552463. Epub 2014 Jun 2.

19.

Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q).

Lai F, Godley LA, Joslin J, Fernald AA, Liu J, Espinosa R 3rd, Zhao N, Pamintuan L, Till BG, Larson RA, Qian Z, Le Beau MM.

Genomics. 2001 Jan 15;71(2):235-45.

PMID:
11161817
20.

Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome.

Jaju RJ, Boultwood J, Oliver FJ, Kostrzewa M, Fidler C, Parker N, McPherson JD, Morris SW, Müller U, Wainscoat JS, Kearney L.

Genes Chromosomes Cancer. 1998 Jul;22(3):251-6.

PMID:
9624537

Supplemental Content

Support Center